Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W Roberts, John F Seymour, Jennifer R Brown, William G Wierda, Thomas J Kipps, Seong Lin Khaw, Dennis A Carney, Simon Z He, David CS Huang, Hao Xiong, Yue Cui, Todd A Busman, Evelyn M McKeegan, Andrew P Krivoshik, Sari H Enschede, Rod Humerickhouse
JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2012
Awarded by NATIONAL CANCER INSTITUTE
Research Funding: Andrew W. Roberts, Abbott Laboratories; Jennifer R. Brown, Celgene, Genzyme; William G. Wierda, GlaxoSmithKline, Abbott Laboratories; Thomas J. Kipps, Abbott LaboratoriesSupported by Abbott Laboratories and Genentech. Additional support for correlative studies was provided by National Health and Medical Research Council of Australia, Victorian Cancer Agency, Leukaemia Foundation Australia, Australian Cancer Research Foundation, and the Leukemia and Lymphoma Society.